<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524612</url>
  </required_header>
  <id_info>
    <org_study_id>CETB115J2411</org_study_id>
    <secondary_id>2018-000452-18</secondary_id>
    <nct_id>NCT03524612</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP</brief_title>
  <acronym>TAPER</acronym>
  <official_title>A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the ability of eltrombopag to induce sustained treatment-free
      remission in ITP subjects who relapsed or failed to respond to an initial treatment with
      steroids.

      There is limited, mainly retrospective evidence that earlier use of eltrombopag after ITP
      diagnosis, will allow a larger proportion of subjects to achieve sustained remission after
      tapering off drug. Clinically there is a need for a less toxic regimen that will provide
      responses and sustained remission with a shorter treatment interval. This trial is designed
      to assess this.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained remission (R) by 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Sustained remission is defined as reach platelet count ≥ 100×109/L (complete response [CR]) and then maintain platelet counts around 100×109/L for 2 months (no counts below 70×109/L) AND then taper off the drug until treatment discontinuation while, maintain platelet count ≥ 30×109/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median duration of sustained remission</measure>
    <time_frame>Last dose of eltrombopag to 12 months</time_frame>
    <description>Duration of sustained remission (in weeks) counted from last dose of eltrombopag to month 12 for participants with sustained remission (R).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with platelet count ≥ 50×109/L</measure>
    <time_frame>By 1 month</time_frame>
    <description>Percentage of subjects who reach platelet count ≥ 50×109/L at least once within the first month (month 1) without bleeding events and no rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least one platelet count ≥ 30×109/L after eltrombopag is re-introduced without bleeding and no rescue medication</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of subjects with at least one platelet count ≥ 30×109/L after eltrombopag is re-introduced, in case of loss of response (&lt; 30×109/L and/or bleeding event) without bleeding events and no rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in platelet count from baseline to various time points</measure>
    <time_frame>Baseline 3, 6, 9, 12 months</time_frame>
    <description>Quantify platelet count from baseline to different time points; box plots for absolute and/or relative change in platelet counts from baseline to different time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who maintain a platelet count ≥ 30×109/L without bleeding and no rescue medication</measure>
    <time_frame>From first time of reaching the level to 3, 6, 9, 12 months</time_frame>
    <description>Ability of eltrombopag to maintain platelet count ≥ 30×109/L within 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionaire</measure>
    <time_frame>Baseline to 3, 6, 9, 12 months</time_frame>
    <description>The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) instrument is a 13-item validated tool used to measure an individual's level of fatigue during usual daily activities over the past 7 days (Cella 2002, Webster 2003). FACIT-Fatigue is a subscale of the FACIT measurement system. FACIT-fatigue is scored using a 4-point Likert scale (4=not at all fatigued to 0=very much fatigued) where the total possible score ranges from 0-5; higher scores represent better HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functinal Assessment of Cancer Therapy- Thrombocytopenia (FACT-Th6) questionnaire</measure>
    <time_frame>Baseline to 3, 6, 9, 12 months</time_frame>
    <description>FACT-Th6 instrument is used to measure worry/concern about bleeding and bruising, and the impact of this worry/concern on physical and social activity (Cella 2006). FACT-Th6 is a 6-item subset of the more detailed FACT-Th, which is an 18-item subscale of the validated FACT that specifically measures concerns related to thrombocytopenia in the past 7 days. The FACT-Th6 is scored using a 5-level Likert scale (0=not at all to 4=very much) and is calculated by summing scores for the 6-items; therefore, scores can range from 0-24, with higher scores representing better HRQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Short Form 36 Health Survey (SF-36v2) questionnaire</measure>
    <time_frame>Baseline to 3, 6, 9, 12 months</time_frame>
    <description>SF-36v2 is a validated instrument used to measure general physical and mental health status (Ware 2000) via assessment of 8 domains—Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health—over the past 4 weeks or 7 days. The SF-36 is scored using norm-based scoring procedures and scores ranging from 0-100; higher scores represent better HRQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall change from baseline of the overall impact of side effects on treatment via Functional Assessment of Cancer Therapy-G (GP5)</measure>
    <time_frame>Baseline, 12 months or end of study</time_frame>
    <description>The GP5 is a single question used to assess the overall bothersomeness of treatment side effects. The GP5 is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bothersomeness from treatment side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall change of treatment satisfaction using Treatment Satisfaction Questionnaire (TSQM-9)</measure>
    <time_frame>Baseline, 12 months or end of study</time_frame>
    <description>TSQM-9 will be used to assess treatment satisfaction with medication. The three scales of the TSQM-9 include the effectiveness scale, convenience scale, and global satisfaction scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>Immune Thrombocytopenic Purpura (ITP)</condition>
  <arm_group>
    <arm_group_label>eltrombopag</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will be treated with eltrombopagto to induce sustained remission to reach a target platelet count of ≥ 100×109/L (CR), after 1st line steroids have failed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag</intervention_name>
    <description>eltrombopag is for oral use and comes in 12.5, 25, 50 and 75 mg tablets; prescribed dose is taken once daily</description>
    <arm_group_label>eltrombopag</arm_group_label>
    <other_name>ETB115</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent must be obtained prior to participation in the study

          2. Subjects ≥ 18 years old

          3. Subjects with a confirmed diagnosis of primary ITP, who are not responsive or in
             relapse after a first line of steroid therapy ± intravenous immunoglobulin (IVIG)
             (used as a rescue therapy)

          4. Platelet count &lt; 30×109/L and assessed as needing treatment (per physician's
             discretion

        Exclusion Criteria:

          1. ITP subjects previously treated with any ITP second-line therapies, thrombopoietin
             receptor (TPO-R) agonists for ITP, except steroids / IVIG

          2. Subjects who relapsed more than one year after the end of first-line full course of
             steroid therapy

          3. Subjects with a diagnosis of secondary thrombocytopenia

          4. Subjects who have life threatening bleeding complications per investigator discretion

          5. Subjects who had a deep vein thrombosis or arterial thrombosis in the 6 months
             preceding enrollment

          6. Serum creatinine ≥ 1.5 mg/dL

          7. Total bilirubin &gt; 1.5 × upper limit of normal (ULN)

          8. Aspartate transaminase (AST) &gt; 3.0 × ULN

          9. Alanine transaminase (ALT) &gt; 3.0 × ULN

         10. Subjects who are human immune deficiency virus (HIV), hepatitis C virus (HCV),
             hepatitis B surface antigen (HBsAg) positive

         11. Subjects with hepatic impairment (Child-Pugh score &gt; 5)

         12. Subjects who have active malignancy

         13. Subjects with any serious and/or unstable pre-existing medical, psychiatric disorder
             or other conditions that could interfere with subject's safety, obtaining informed
             consent or compliance with the study procedures per investigator discretion

         14. History or current diagnosis of cardiac disease indicating significant risk of safety
             for subjects participating in the study

         15. Subjects with known active or uncontrolled infections not responding to appropriate
             therapy

         16. Subjects with evidence of current alcohol/drug abuse

         17. Women of child-bearing potential and sexually active males unwilling to use adequate
             contraception during the study

         18. Female subjects who are nursing or pregnant (positive serum or urine B-human chorionic
             gonadotrophin (B-hCG) pregnancy test) at screening or pre-dose on Day 1

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>323-422-1963</phone>
    </contact>
    <investigator>
      <last_name>Howard Liebman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Ciciriello</last_name>
      <email>allan.ciciriello@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Ana Antun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Association of Rockland Drug Shipment</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Abraham</last_name>
      <phone>845-348-2657</phone>
      <email>abrahamj@highlandmedicalpc.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve SC - 2</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-844-7405</phone>
    </contact>
    <investigator>
      <last_name>Ankit Mangla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Cuker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Truong</last_name>
      <phone>713-363-7537</phone>
      <email>mtruong@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Rice</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A-1090 Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vina del Mar</city>
        <state>Valparaiso</state>
        <zip>2540364</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion Crete</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shiwa-gun</city>
        <state>Iwate</state>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muscat</city>
        <zip>123</zip>
        <country>Oman</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muensterlingen</city>
        <state>CHE</state>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aydin</city>
        <zip>09100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Oman</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>April 18, 2020</last_update_submitted>
  <last_update_submitted_qc>April 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombocytopenic</keyword>
  <keyword>Immune</keyword>
  <keyword>Platelets</keyword>
  <keyword>Bleeding</keyword>
  <keyword>ITP</keyword>
  <keyword>eltrombopag</keyword>
  <keyword>ETB115</keyword>
  <keyword>induce sustained remission</keyword>
  <keyword>refractory or relapsed</keyword>
  <keyword>first-line steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

